Therefore, these results further support that GPR87 upregulation promotes the aggressiveness of pancreatic cancer and activates the NF-κB signaling pathway, which potentially leads to poor outcomes for patients with pancreatic cancer. This evidence concerns the gene NFKB1 and pancreatic neoplasm.